Joette M. Meyer, PharmD; Nancy P. Silliman, PhD; Wenjin Wang, PhD; Nancy Y. Siepman, PhD; Jennifer E. Sugg, MS; David Morris, PhD; Jie Zhang, PhD; Helen Bhattacharyya, PhD; Eileen C. King, PhD; Robert J. Hopkins, MD, MPH + TM
Disclaimer: This article contains the professional views of the authors and does not necessarily represent the official position of the U.S. Food and Drug Administration.
Requests for Single Reprints: Joette M. Meyer, PharmD, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Division of Pharmaceutical Evaluation III (HFD-880), 9201 Corporate Boulevard, Room S-402, Rockville, MD 20850.
Current Author Addresses: Dr. Meyer: Division of Drug Evaluation III (HFD-880), 9201 Corporate Boulevard, Room S-402, Rockville, MD 20850.
Dr. Silliman: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Division of Biostatistics III (HFD-725), 9201 Corporate Boulevard, Rockville, MD 20850.
Dr. Wang: Wyeth-Ayerst Research, Box 8299, Philadelphia, PA 19101.
Dr. Siepman: TAP Pharmaceutical Products, Inc., 675 North Field Drive, Lake Forest, IL 60045.
Ms. Sugg: AstraZeneca L.P., 725 Chesterbrook Boulevard, D-3W, Wayne, PA 19087-5677.
Drs. Morris and Zhang: Abbott Laboratories, 100 Abbott Park Road, D-491, AP6B-1SW, Abbott Park, IL 60064-6124.
Dr. Bhattacharyya: Pfizer Central Research, 235 East 42nd Street, New York, NY 10017-5755.
Dr. King: Procter & Gamble Pharmaceuticals, Inc., Box 8006, Mason, OH 45040.
Dr. Hopkins: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Division of Special Pathogen and Immunologic Drug Products (HFD-590), 9201 Corporate Boulevard, Rockville, MD 20850.
Author Contributions: Conception and design: J.M. Meyer, R.J. Hopkins.
Analysis and interpretation of the data: J.M. Meyer, N.P. Silliman.
Drafting of the article: J.M. Meyer, R.J. Hopkins.
Critical revision of the article for important intellectual content: J.M. Meyer, N.P. Silliman, N.Y. Siepman, J.E. Sugg, D. Morris, J. Zhang, R.J. Hopkins.
Final approval of the article: J.M. Meyer, N.P. Silliman, N.Y. Siepman, E.C. King, H. Bhattacharyya, R.J. Hopkins.
Statistical expertise: N.P. Silliman, W. Wang, N.Y. Siepman, D. Morris, J. Zhang, E.C. King.
Collection and assembly of data: J.M. Meyer, W. Wang, N.Y. Siepman, J.E. Sugg, D. Morris, J. Zhang, H. Bhattacharyya, E.C. King.
Meyer JM, Silliman NP, Wang W, Siepman NY, Sugg JE, Morris D, et al. Risk Factors for Helicobacter pylori Resistance in the United States: The Surveillance of H. pylori Antimicrobial Resistance Partnership (SHARP) Study, 1993–1999. Ann Intern Med. 2002;136:13-24. doi: 10.7326/0003-4819-136-1-200201010-00008
Download citation file:
Published: Ann Intern Med. 2002;136(1):13-24.
Helicobacter pylori is the major pathologic agent in the development of gastric and duodenal ulcers, and H. pylori eradication is known to reduce recurrence of peptic ulcers (1). In addition, infection has been linked to chronic active gastritis, gastric carcinoma, mucosa-associated lymphoid-tissue lymphoma, and possibly nonulcer dyspepsia. Pretreatment antimicrobial resistance has an important negative impact on the efficacy of many H. pylori treatment regimens. Although researchers have attempted to evaluate H. pylori resistance in the United States (2-4), risk factors associated with antimicrobial resistance have not been well characterized. Identification of such risk factors is of particular interest in H. pylori infection, for which treatment is usually prescribed without knowledge of the susceptibility of the individual patient's isolate.
Learn more about subscription options.
Register Now for a free account.
Gastroenterology/Hepatology, Infectious Disease, Peptic Disease, H. Pylori.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only